Physician profile
Ivan S Ayala
NPI 1952345944
$4,538.06
in general payments reported to CMS, 2019-2025
18 companies · $312 in 2025
The $312 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $991 · 2020: $1,645 · 2021: $549 · 2022: $351 · 2023: $483 · 2024: $207 · 2025: $312.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,002.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,001.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,889.24 | 2019-2024 | Xarelto, Invokana |
| Medtronic, INC. | $702.34 | 2019-2021 | |
| Pbg Puerto Rico LLC | $541.47 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $328.93 | 2019-2023 | Jardiance |
| Amgen INC. | $179.00 | 2019-2025 | Repatha |
| Boston Scientific Corporation | $161.11 | 2019-2025 | General - Tachy, General - Therapies |
| Impulse Dynamics (USA) INC. | $121.91 | 2023 | Optimizer |
| E.R. Squibb & Sons, L.L.C. | $105.36 | 2021-2025 | Eliquis |
| Novartis Pharmaceuticals Corporation | $100.00 | 2019 | |
| Merck Sharp & Dohme LLC | $97.93 | 2019-2024 | Verquvo, Janumet, Januvia |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $71.24 | 2019-2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $60.55 | 2019-2020 | |
| Abbott Laboratories | $59.85 | 2022 | |
| Ge Healthcare | $48.10 | 2019 | |
| Biotronik INC. | $24.49 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $21.19 | 2019 | |
| Pfizer Pharmaceuticals LLC | $17.00 | 2019 | |
| Pfizer INC. | $8.35 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ivan Ayala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.